Key result
SP1 mediates SFRP5 loss during atrial fibrillation by transcriptional repression, contributing to cardiac fibrosis and myocyte apoptosis, which can be mitigated by SFRP5 restoration or SP1 knockdown.
Why the study?
SFRP5 is a cardioprotective protein with diminished expression in AF, but its function in AF-related cardiac fibrosis and cardiomyocyte apoptosis and the causes of its dysregulation remained to be investigated.
SP1-mediated transcriptional repression of SFRP5 contributes to AF-related cardiac fibrosis and myocyte apoptosis, highlighting the SFRP5-SP1 axis as a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
SFRP5-SP1 modulation attenuates fibrosis in rodent AF; leaves open whether this axis is druggable in patients.
Secreted frizzled related protein 5 (SFRP5) is a recognized cardioprotective protein with diminished expression in atrial fibrillation (AF). This study investigates SFRP5's function in AF-related cardiac fibrosis and cardiomyocyte apoptosis, exploring the underlying dysregulation causes. Utilizing C57BL/6 mice, mouse cardiac fibroblasts (CFs), and HC-1 mouse atrial myocyte cell line, AF models were induced by angiotensin Ⅱ (Ang Ⅱ). SFRP5 levels were consistently decreased in plasma samples from clinical patients, modeled mice, and CF culture supernatants. Treatment with recombinant SFRP5 restored its levels, mitigating Ang Ⅱ-induced AF in mice and ameliorating atrial tissue fibrosis and oxidative stress. In vitro, SFRP5 recombinant protein suppressed CF activation and fibrosis-related markers. The study identified Sp1 transcription factor (SP1) binding to the SFRP5 promoter, causing transcriptional repression. SP1 knockdown reinstated SFRP5 levels in mice and CFs, thus suppressing fibrosis. Additionally, SP1 knockdown attenuated Ang Ⅱ-induced apoptosis in HC-1 cells, but this effect was counteracted by concurrent SFRP5 knockdown. In conclusion, this investigation underscores that SP1 mediates SFRP5 loss during AF by transcriptional repression, contributing to fibrosis and myocyte apoptosis. These findings illuminate potential therapeutic interventions targeting the SFRP5-SP1 axis in AF-related cardiac complications.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2024) studied Atrial fibrillation. SFRP5 recombinant protein and SP1 knockdown vs. Angiotensin II-induced AF models was evaluated on Cardiac fibrosis and cardiomyocyte apoptosis. SP1 mediates SFRP5 loss during atrial fibrillation by transcriptional repression, contributing to cardiac fibrosis and myocyte apoptosis, which can be mitigated by SFRP5 restoration or SP1 knockdown.
Synapse has enriched 10 related papers. Consider them for comparative context: